What We Do
About Us
Cure Leukaemia was established in 2003 by Professor Charlie Craddock CBE and patients Graham Silk and Michael Woolley to allow patients with blood cancer in the Birmingham region to access remarkably effective new treatments which were then becoming available.
Since then, Cure Leukaemia has been able to expand to a national level, and we are now able to offer potential life-saving treatment to patients across the UK. This support drives global significant advancements in blood cancer, impacting those affected by the disease worldwide.
Thanks to our huge CL Family of dedicated fundraisers, we’ve been able to continue to grow each year and connect more patients to potentially lifesaving treatment.
The Trials Acceleration Programme (TAP Network)
The TAP Network allows patients to be connected with world-class and potentially lifesaving treatment that would otherwise not be available to them through standard care.
The TAP network allows a catchment area of over 20,000,000 patients to be connected with world-class and potentially lifesaving treatments that would otherwise not be available to them through standard care – with over 40,000 people diagnosed with blood cancer every year.
ATICUS Network (Paediatric Transplant Trials Network)
Cure Leukaemia launched in September 2024 The ATICUS Network. The Paediatric Network brings together the UK’s leading paediatric clinicians and research nurses to deliver cutting-edge, practice-changing clinical trials aimed at improving outcomes for children undergoing stem cell transplants. Operating across ten major metropolitan cities, including Manchester, London, Birmingham, and Glasgow, this groundbreaking initiative ensures that transformative new therapies will be more readily available to children who need them most.
What is a Clinical Trial?
